DOCSLIB.ORG

Collagen Degradation and MMP9 Activation by Enterococcus Faecalis Contribute to Intestinal Anastomotic Leak

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Collagen Degradation and MMP9 Activation by Enterococcus Faecalis Contribute to Intestinal Anastomotic Leak RESEARCH ARTICLE WOUND HEALING Collagen degradation and MMP9 activation by Enterococcus faecalis contribute to intestinal anastomotic leak Benjamin D. Shogan,1 Natalia Belogortseva,1 Preston M. Luong,1 Alexander Zaborin,1 Simon Lax,1 Cindy Bethel,1 Marc Ward,1 Joseph P. Muldoon,2 Mark Singer,2 Gary An,1 Konstantin Umanskiy,1 Vani Konda,1 Baddr Shakhsheer,1 James Luo,1 Robin Klabbers,1,3 Lynn E. Hancock,4 Jack Gilbert,1,5 Olga Zaborina,1* John C. Alverdy1*† Even under the most expert care, a properly constructed intestinal anastomosis can fail to heal, resulting in leakage of its contents, peritonitis, and sepsis. The cause of anastomotic leak remains unknown, and its incidence has not changed in decades. We demonstrate that the commensal bacterium Enterococcus faecalis contributes to the patho- genesis of anastomotic leak through its capacity to degrade collagen and to activate tissue matrix metalloproteinase 9 (MMP9) in host intestinal tissues. We demonstrate in rats that leaking anastomotic tissues were colonized by E. faecalis strains that showed an increased collagen-degrading activity and also an increased ability to activate host MMP9, both of which contributed to anastomotic leakage. We demonstrate that the E. faecalis genes gelE and sprE were required for E. faecalis–mediated MMP9 activation. Either elimination of E. faecalis strains through direct topical antibiotics applied to rat intestinal tissues or pharmacological suppression of intestinal MMP9 ac- tivation prevented anastomotic leak in rats. In contrast, the standard recommended intravenous antibiotics used in patients undergoing colorectal surgery did not eliminate E. faecalis at anastomotic tissues nor did they prevent leak in our rat model. Finally, we show in humans undergoing colon surgery and treated with the standard rec- on May 7, 2015 ommended intravenous antibiotics that their anastomotic tissues still contained E. faecalis and other bacterial strains with collagen-degrading/MMP9-activating activity. We suggest that intestinal microbes with the capacity to produce collagenases and to activate host metalloproteinase MMP9 may break down collagen in the intestinal tissue contributing to anastomotic leak. INTRODUCTION who demonstrated that repeated direct topical application of anti- The most devastating complication after removal of an intestinal seg- biotics onto anastomotic tissues accelerated healing and prevented stm.sciencemag.org ment (resection) and its reconnection (anastomosis) is an anastomotic leak in dogs undergoing colon resection and anastomosis when the leak. The clinical manifestations of an anastomotic leak range from ab- supplying blood vessels were divided in a manner that resulted in gross dominal pain with fever to septic shock. In its extreme form, anastomotic ischemia (2). Remarkably, despite the grossly visible presence of is- leak can cause peritonitis, sepsis, and even death. Leaks are particularly chemia, direct topical application of antibiotics not only prevented prevalent in patients undergoing surgery in high-risk regions of the anastomotic leak but also completely reversed the ischemia. Although intestine such as the rectum and esophagus (1). In the distal colon and from 1955 to 1984 oral antibiotics were introduced as a routine part of rectal area, the anastomotic leak rate can be excessive (30 to 40%), forcing the preparation of gastrointestinal surgery, they were soon replaced by surgeons to routinely perform a protective diverting stoma (ileostomy intravenous antibiotics owing primarily to the convenience of admin- Downloaded from and colostomy) to lessen the clinical effects of intestinal content spillage istration and the perception that they were equally efficacious in de- (1). This practice requires a second operation to close the diverting contaminating anastomotic tissues of potentially offending pathogens stoma, which itself carries significant morbidity and includes the risk (3, 4). Despite numerous studies demonstrating the benefit of adding of an anastomotic leak. Consequently, many patients and surgeons elect oral antibiotics before gastrointestinal surgery to prevent infection and to leave the stoma as a permanent solution to avoid a second high-risk anastomotic leak, most surgeons do not routinely administer oral an- surgery. Given this, there is little motivation among surgeons to elimi- tibiotics in preparation for gastrointestinal surgery (3, 4). We have nate the routine use of a diverting stoma in lower colorectal surgery be- recently published work that readdresses the role of bacteria in anas- cause they have accepted that the actual causes of anastomotic leaks tomotic leak in a more molecular context (5). We reported that expo- remain unknown and hence they are not preventable. sure of anastomotic tissues to pathogenic bacteria such as Pseudomonas That intestinal microbes play a key causative role in the patho- aeruginosa resulted in selection of a more virulent phenotype characterized genesis of anastomotic leak has been suggested for over 60 years. by high collagen-degrading activity, which was associated with anastomotic The most direct evidence was first reported in 1955 by Cohn and Rives, leak (5). We hypothesized that the capacity of intestinal bacteria to degrade collagen may be an important mechanism underlying anastomotic leak. To 1University of Chicago Pritzker School of Medicine, Chicago, IL 60637, USA. 2NorthShore identify additional and, perhaps, more common bacteria with collagen- University HealthSystem, Evanston, IL 60201, USA. 3Department of Surgery, Radboud degrading activity that might colonize anastomotic tissues after surgery, 4 University Nijmegen Medical Centre, Nijmegen, Netherlands. The University of Kansas, we next examined the microflora associated with anastomotic tissues using Lawrence, KS 66045, USA. 5Argonne National Laboratory, Argonne, IL 60439, USA. *Senior co-authors. 16S rRNA (ribosomal RNA) and PICRUSt (Phylogenetic Investigation †Corresponding author. E-mail: [email protected] of Communities by Reconstruction of Unobserved States) analyses in www.ScienceTranslationalMedicine.org 6 May 2015 Vol 7 Issue 286 286ra68 1 RESEARCH ARTICLE rats after anastomotic surgery (6). Results A B C x104 C x104 demonstrated a 500-fold increase in the 1 cm 100 6 6 relative abundance of the genus Enterococcus * Dvasc 80 5 * 5 at the anastomotic site. The PICRUSt func- 60 4 4 tional analysis (7) predicted the predomi- Anast 40 3 3 nance of several bacterial virulence factors, 20 2 2 1 Dvasc 1 one of which, coccolysin [GelE (gelatin- 1 cm 0 + 0 Dvasc – activity, Collagen-degrading RFU/OD 600 nm 0 ase)], is responsible for collagen/gelatin % leak rate, Anastomotic Dvasc – ++– Anast + + Anast – – ++ Heal Leak degradation (8, 9). These findings, coupled with the observations that bacterial-derived D Sham Dvasc Anast Dvasc+Anast Dvasc+Anast heal leak collagenases are known to play an important C role in a variety of intestinal disorders such as those involving inflammation and necrosis, led us to explore the role of Enterococcus in anastomotic leak (10–15). Here, we demonstrate that among com- 4 mensal microbiota, Enterococcus faecalis E E F x10 strains with enhanced collagen-degrading 5 activity and the capacity to activate intestinal 60 60 4 50 50 40 3 tissue matrix metalloproteinase 9 (MMP9) 40 30 30 2 contribute to the pathogenesis of anasto- 20 motic leak. 10 20 10 1 Collagen content, % content, Collagen 0 * Dvasc – + – + 0 activity, Collagen-degrading RFU/OD 600 nm 0 Anast – – ++ Heal Leak E. coli E. hirae on May 7, 2015 E. faecalis M. morganii P. mirabilis E. gallinarum pneumoniae RESULTS K. G H I J Gelatin K 4 4 Collagen I Clinical outcome of rats after x10 x10 surgery demonstrates that while 50 100 Collagen IV 3 3 80 40 80 intestinal devascularization is 60 2 2 associated with leak, it does not 30 60 40 20 40 1 20 cause gross ischemia 1 % rate, Leak % rate, Leak 10 20 stm.sciencemag.org 0 0 We created an anastomotic leak model in % content, Collagen 0 0 Collagen-degrading activity, activity, Collagen-degrading RFU/OD 600 nm 0 E1 E2 ∆ 2 activity, Collagen-degrading RFU/OD 600 nm ∆ ∆ sprE rats by performing a 1-cm colon resection E1 E2 E1 E V583 gelE sprE ∆ ∆gelE Sham Heal Leak ∆gelE sprE (at the peritoneal reflection) and primary No bacteria No bacteria anastomosis, followed by devasculariza- ∆gelE∆sprE/gelE+sprE tion of a 2-cm segment of blood supply Fig. 1. E. faecalis with high collagen-degrading activity is associated with anastomotic leak. (A)Rat adjacent to the anastomosis (Fig. 1A). All model of anastomotic leak. (B) Incidence of leak between devascularized (Dvasc) versus nondevascularized rats that survived did well after surgery and (Anast) intestinal segments of the rat model (n =15;*P < 0.01). (C) Collagen-degrading activity of whole mi- were healthy-appearing at the time of sac- crobial communities between various groups of rats showing that microbial collagen-degrading activity dis- Downloaded from rifice [postoperative day 6 (POD6)] as criminated between leaking versus nonleaking groups (n =10pergroup;*P <0.01,Student’s t test). RFU, judged by their feeding pattern, movement relative fluorescence unit; OD, optical density. (D) Trichrome staining of representative rat intestinal segments in the cage, and stool passage. There were demonstrates collagen depletion and leakage. Collagen is shown by a white arrow. (E) Trichrome stain density occasional anesthesia-related deaths (<5) between treatment groups discriminated between rats with and without
Load more

Recommended publications
  • Serine Proteases with Altered Sensitivity to Activity-Modulating
    (19) & (11) EP 2 045 321 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.04.2009 Bulletin 2009/15 C12N 9/00 (2006.01) C12N 15/00 (2006.01) C12Q 1/37 (2006.01) (21) Application number: 09150549.5 (22) Date of filing: 26.05.2006 (84) Designated Contracting States: • Haupts, Ulrich AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 51519 Odenthal (DE) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Coco, Wayne SK TR 50737 Köln (DE) •Tebbe, Jan (30) Priority: 27.05.2005 EP 05104543 50733 Köln (DE) • Votsmeier, Christian (62) Document number(s) of the earlier application(s) in 50259 Pulheim (DE) accordance with Art. 76 EPC: • Scheidig, Andreas 06763303.2 / 1 883 696 50823 Köln (DE) (71) Applicant: Direvo Biotech AG (74) Representative: von Kreisler Selting Werner 50829 Köln (DE) Patentanwälte P.O. Box 10 22 41 (72) Inventors: 50462 Köln (DE) • Koltermann, André 82057 Icking (DE) Remarks: • Kettling, Ulrich This application was filed on 14-01-2009 as a 81477 München (DE) divisional application to the application mentioned under INID code 62. (54) Serine proteases with altered sensitivity to activity-modulating substances (57) The present invention provides variants of ser- screening of the library in the presence of one or several ine proteases of the S1 class with altered sensitivity to activity-modulating substances, selection of variants with one or more activity-modulating substances. A method altered sensitivity to one or several activity-modulating for the generation of such proteases is disclosed, com- substances and isolation of those polynucleotide se- prising the provision of a protease library encoding poly- quences that encode for the selected variants.
    [Show full text]
  • Doktorarbeit 120304Docx
    TECHNISCHE UNIVERSITÄT MÜNCHEN Lehrstuhl für Biofunktionalität der Lebensmittel Mechanistic impact of Enterococcus faecalis metalloprotease on bacterial virulence in the context of chronic intestinal inflammation Natalie Marie Annabel Steck Vollständiger Abdruck der von der Fakultät Wissenschaftszentrum Weihenstephan für Ernährung, Landnutzung und Umwelt der Technischen Universität München zur Erlangung des akademischen Grades eines Doktors der Naturwissenschaften genehmigten Dissertation. Vorsitzender: Univ.-Prof. Dr. M. Schemann Prüfer der Dissertation: 1. Univ.-Prof. Dr. D. Haller 2. Univ.-Prof. Dr. R.F. Vogel Die Dissertation wurde am 17.11.2011 bei der Technischen Universität München eingereicht und durch die Fakultät Wissenschaftszentrum Weihenstephan für Ernährung, Landnutzung und Umwelt am 06.02.2012 angenommen. Für meine Familie und Freunde PUBLICATIONS AND PRESENTATIONS PUBLICATIONS AND PRESENTATIONS Peer-reviewed original manuscripts and reviews Steck N*, Mueller K*, Schemann M and Haller D. Bacterial proteases in IBD and IBS. Gut, 2011 (*authors equally contributed to the manuscript) Steck N , Hoffmann M, Sava IG, Kim SC, Hahne H, Tonkonogy SL, Mair K, Krueger D, Pruteanu M, Shanahan F, Vogelmann R, Schemann M, Kuster B, Sartor RB and Haller D. Enterococcus faecalis Metalloprotease Compromises Epithelial Barrier and Contributes to Intestinal Inflammation. Gastroenterology, 2011 Sep;141(3):959-71. Published abstracts Steck N , Hoffmann M, Hew Ferstl CM, Kim SC, Tonkonogy SL, Vogel RF, Sartor RB, Haller D. E. faecalis Gelatinase contributes to the development of intestinal inflammation by impairing epithelial barrier function: Role for bacteria-derived proteases in the pathology of IBD. Journal of Crohn's and Colitis Supplements - April 2010, Vol. 4, Issue 1, Pages 22-23 Steck N , Hoffmann M, Hew Ferstl CM, Kim SC, Liu B, Vogel RF, Sartor RB, Haller D.
    [Show full text]
  • Handbook of Proteolytic Enzymes Second Edition Volume 1 Aspartic and Metallo Peptidases
    Handbook of Proteolytic Enzymes Second Edition Volume 1 Aspartic and Metallo Peptidases Alan J. Barrett Neil D. Rawlings J. Fred Woessner Editor biographies xxi Contributors xxiii Preface xxxi Introduction ' Abbreviations xxxvii ASPARTIC PEPTIDASES Introduction 1 Aspartic peptidases and their clans 3 2 Catalytic pathway of aspartic peptidases 12 Clan AA Family Al 3 Pepsin A 19 4 Pepsin B 28 5 Chymosin 29 6 Cathepsin E 33 7 Gastricsin 38 8 Cathepsin D 43 9 Napsin A 52 10 Renin 54 11 Mouse submandibular renin 62 12 Memapsin 1 64 13 Memapsin 2 66 14 Plasmepsins 70 15 Plasmepsin II 73 16 Tick heme-binding aspartic proteinase 76 17 Phytepsin 77 18 Nepenthesin 85 19 Saccharopepsin 87 20 Neurosporapepsin 90 21 Acrocylindropepsin 9 1 22 Aspergillopepsin I 92 23 Penicillopepsin 99 24 Endothiapepsin 104 25 Rhizopuspepsin 108 26 Mucorpepsin 11 1 27 Polyporopepsin 113 28 Candidapepsin 115 29 Candiparapsin 120 30 Canditropsin 123 31 Syncephapepsin 125 32 Barrierpepsin 126 33 Yapsin 1 128 34 Yapsin 2 132 35 Yapsin A 133 36 Pregnancy-associated glycoproteins 135 37 Pepsin F 137 38 Rhodotorulapepsin 139 39 Cladosporopepsin 140 40 Pycnoporopepsin 141 Family A2 and others 41 Human immunodeficiency virus 1 retropepsin 144 42 Human immunodeficiency virus 2 retropepsin 154 43 Simian immunodeficiency virus retropepsin 158 44 Equine infectious anemia virus retropepsin 160 45 Rous sarcoma virus retropepsin and avian myeloblastosis virus retropepsin 163 46 Human T-cell leukemia virus type I (HTLV-I) retropepsin 166 47 Bovine leukemia virus retropepsin 169 48
    [Show full text]
  • The Detrimental Impact of Extracellular Bacterial Proteases on Wound Healing
    1 Title: The detrimental impact of extracellular bacterial proteases on wound healing 2 3 Running title: Bacterial proteases 4 5 Authors: Sharon Lindsay1, Angela Oates2, Katie Bourdillon1 6 7 Author affiliations: 8 1 Systagenix Wound Management Gargrave N. Yorkshire BD23 3RX UK 9 2School of Pharmacy and Pharmaceutical Sciences, The University of Manchester, 10 Manchester, M13 9PT, UK 11 12 Corresponding author: 13 Katie Bourdillon 14 Key words: 15 Virulence factor, bacterial protease, wound infection, point-of-care diagnostic 16 Article: This is the peer reviewed version of the following article: Lindsay, S, Oates, A orcid.org/0000-0003-0519-4556 and Bourdillon, K (2017) The detrimental impact of extracellular bacterial proteases on wound healing. International Wound Journal, 14 (6). pp. 1237-1247. ISSN 1742-4801 which has been published in final form at https://doi.org/10.1111/ iwj.12790. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. 1 17 Abstract 18 In addition to clinical signs of infection (e.g. inflammation, purulence and pain), a microbial 19 20 However, it is increasingly recognised that, rather than a high bioburden level alone being 21 detrimental to wound healing, it is the virulence of the invading microorganism and the host's 22 immune status that can affect clinical outcomes. Bacteria, such as Pseudomonas aeruginosa, 23 Staphylococcus aureus and Staphylococcus epidermidis, have developed a range of virulence 24 factorsto helpthemovercome hostdefences andproliferate within the underlying soft tissue. 25 More specifically, bacterial proteases are one such virulence factor that has been implicated 26 in promoting the invasion and destruction of the host tissue.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0081648A1 Afeyan Et Al
    US 2004.008 1648A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0081648A1 Afeyan et al. (43) Pub. Date: Apr. 29, 2004 (54) ADZYMES AND USES THEREOF Publication Classification (76) Inventors: Noubar B. Afeyan, Lexington, MA (51) Int. Cl." ............................. A61K 38/48; C12N 9/64 (US); Frank D. Lee, Chestnut Hill, MA (52) U.S. Cl. ......................................... 424/94.63; 435/226 (US); Gordon G. Wong, Brookline, MA (US); Ruchira Das Gupta, Auburndale, MA (US); Brian Baynes, (57) ABSTRACT Somerville, MA (US) Disclosed is a family of novel protein constructs, useful as Correspondence Address: drugs and for other purposes, termed “adzymes, comprising ROPES & GRAY LLP an address moiety and a catalytic domain. In Some types of disclosed adzymes, the address binds with a binding site on ONE INTERNATIONAL PLACE or in functional proximity to a targeted biomolecule, e.g., an BOSTON, MA 02110-2624 (US) extracellular targeted biomolecule, and is disposed adjacent (21) Appl. No.: 10/650,592 the catalytic domain So that its affinity Serves to confer a new Specificity to the catalytic domain by increasing the effective (22) Filed: Aug. 27, 2003 local concentration of the target in the vicinity of the catalytic domain. The present invention also provides phar Related U.S. Application Data maceutical compositions comprising these adzymes, meth ods of making adzymes, DNA's encoding adzymes or parts (60) Provisional application No. 60/406,517, filed on Aug. thereof, and methods of using adzymes, Such as for treating 27, 2002. Provisional application No. 60/423,754, human Subjects Suffering from a disease, Such as a disease filed on Nov.
    [Show full text]
  • 12) United States Patent (10
    US007635572B2 (12) UnitedO States Patent (10) Patent No.: US 7,635,572 B2 Zhou et al. (45) Date of Patent: Dec. 22, 2009 (54) METHODS FOR CONDUCTING ASSAYS FOR 5,506,121 A 4/1996 Skerra et al. ENZYME ACTIVITY ON PROTEIN 5,510,270 A 4/1996 Fodor et al. MICROARRAYS 5,512,492 A 4/1996 Herron et al. 5,516,635 A 5/1996 Ekins et al. (75) Inventors: Fang X. Zhou, New Haven, CT (US); 5,532,128 A 7/1996 Eggers Barry Schweitzer, Cheshire, CT (US) 5,538,897 A 7/1996 Yates, III et al. s s 5,541,070 A 7/1996 Kauvar (73) Assignee: Life Technologies Corporation, .. S.E. al Carlsbad, CA (US) 5,585,069 A 12/1996 Zanzucchi et al. 5,585,639 A 12/1996 Dorsel et al. (*) Notice: Subject to any disclaimer, the term of this 5,593,838 A 1/1997 Zanzucchi et al. patent is extended or adjusted under 35 5,605,662 A 2f1997 Heller et al. U.S.C. 154(b) by 0 days. 5,620,850 A 4/1997 Bamdad et al. 5,624,711 A 4/1997 Sundberg et al. (21) Appl. No.: 10/865,431 5,627,369 A 5/1997 Vestal et al. 5,629,213 A 5/1997 Kornguth et al. (22) Filed: Jun. 9, 2004 (Continued) (65) Prior Publication Data FOREIGN PATENT DOCUMENTS US 2005/O118665 A1 Jun. 2, 2005 EP 596421 10, 1993 EP 0619321 12/1994 (51) Int. Cl. EP O664452 7, 1995 CI2O 1/50 (2006.01) EP O818467 1, 1998 (52) U.S.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,561,811 B2 Bluchel Et Al
    USOO8561811 B2 (12) United States Patent (10) Patent No.: US 8,561,811 B2 Bluchel et al. (45) Date of Patent: Oct. 22, 2013 (54) SUBSTRATE FOR IMMOBILIZING (56) References Cited FUNCTIONAL SUBSTANCES AND METHOD FOR PREPARING THE SAME U.S. PATENT DOCUMENTS 3,952,053 A 4, 1976 Brown, Jr. et al. (71) Applicants: Christian Gert Bluchel, Singapore 4.415,663 A 1 1/1983 Symon et al. (SG); Yanmei Wang, Singapore (SG) 4,576,928 A 3, 1986 Tani et al. 4.915,839 A 4, 1990 Marinaccio et al. (72) Inventors: Christian Gert Bluchel, Singapore 6,946,527 B2 9, 2005 Lemke et al. (SG); Yanmei Wang, Singapore (SG) FOREIGN PATENT DOCUMENTS (73) Assignee: Temasek Polytechnic, Singapore (SG) CN 101596422 A 12/2009 JP 2253813 A 10, 1990 (*) Notice: Subject to any disclaimer, the term of this JP 2258006 A 10, 1990 patent is extended or adjusted under 35 WO O2O2585 A2 1, 2002 U.S.C. 154(b) by 0 days. OTHER PUBLICATIONS (21) Appl. No.: 13/837,254 Inaternational Search Report for PCT/SG2011/000069 mailing date (22) Filed: Mar 15, 2013 of Apr. 12, 2011. Suen, Shing-Yi, et al. “Comparison of Ligand Density and Protein (65) Prior Publication Data Adsorption on Dye Affinity Membranes Using Difference Spacer Arms'. Separation Science and Technology, 35:1 (2000), pp. 69-87. US 2013/0210111A1 Aug. 15, 2013 Related U.S. Application Data Primary Examiner — Chester Barry (62) Division of application No. 13/580,055, filed as (74) Attorney, Agent, or Firm — Cantor Colburn LLP application No.
    [Show full text]
  • Peptide Sequence
    Peptide Sequence Annotation AADHDG CAS-L1 AAEAISDA M10.005-stromelysin 1 (MMP-3) AAEHDG CAS-L2 AAEYGAEA A01.009-cathepsin D AAGAMFLE M10.007-stromelysin 3 (MMP-11) AAQNASMW A06.001-nodavirus endopeptidase AASGFASP M04.003-vibriolysin ADAHDG CAS-L3 ADAPKGGG M02.006-angiotensin-converting enzyme 2 ADATDG CAS-L5 ADAVMDNP A01.009-cathepsin D ADDPDG CAS-21 ADEPDG CAS-L11 ADETDG CAS-22 ADEVDG CAS-23 ADGKKPSS S01.233-plasmin AEALERMF A01.009-cathepsin D AEEQGVTD C03.007-rhinovirus picornain 3C AETFYVDG A02.001-HIV-1 retropepsin AETWYIDG A02.007-feline immunodeficiency virus retropepsin AFAHDG CAS-L24 AFATDG CAS-25 AFDHDG CAS-L26 AFDTDG CAS-27 AFEHDG CAS-28 AFETDG CAS-29 AFGHDG CAS-30 AFGTDG CAS-31 AFQHDG CAS-32 AFQTDG CAS-33 AFSHDG CAS-L34 AFSTDG CAS-35 AFTHDG CAS-L36 AGERGFFY Insulin B-chain AGLQRGGG M14.004-carboxypeptidase N AGSHLVEA Insulin B-chain AIDIDG CAS-L37 AIDPDG CAS-38 AIDTDG CAS-39 AIDVDG CAS-L40 AIEHDG CAS-L41 AIEIDG CAS-L42 AIENDG CAS-43 AIEPDG CAS-44 AIEQDG CAS-45 AIESDG CAS-46 AIETDG CAS-47 AIEVDG CAS-48 AIFQGPID C03.007-rhinovirus picornain 3C AIGHDG CAS-49 AIGNDG CAS-L50 AIGPDG CAS-L51 AIGQDG CAS-52 AIGSDG CAS-53 AIGTDG CAS-54 AIPMSIPP M10.051-serralysin AISHDG CAS-L55 AISNDG CAS-L56 AISPDG CAS-57 AISQDG CAS-58 AISSDG CAS-59 AISTDG CAS-L60 AKQRAKRD S08.071-furin AKRQGLPV C03.007-rhinovirus picornain 3C AKRRAKRD S08.071-furin AKRRTKRD S08.071-furin ALAALAKK M11.001-gametolysin ALDIDG CAS-L61 ALDPDG CAS-62 ALDTDG CAS-63 ALDVDG CAS-L64 ALEIDG CAS-L65 ALEPDG CAS-L66 ALETDG CAS-67 ALEVDG CAS-68 ALFQGPLQ C03.001-poliovirus-type picornain
    [Show full text]
  • Identification of Surface Proteins in Enterococcus Faecalis V583
    Bøhle et al. BMC Genomics 2011, 12:135 http://www.biomedcentral.com/1471-2164/12/135 RESEARCHARTICLE Open Access Identification of surface proteins in Enterococcus faecalis V583 Liv Anette Bøhle1, Tahira Riaz1, Wolfgang Egge-Jacobsen2, Morten Skaugen1, Øyvind L Busk1, Vincent GH Eijsink1, Geir Mathiesen1* Abstract Background: Surface proteins are a key to a deeper understanding of the behaviour of Gram-positive bacteria interacting with the human gastro-intestinal tract. Such proteins contribute to cell wall synthesis and maintenance and are important for interactions between the bacterial cell and the human host. Since they are exposed and may play roles in pathogenicity, surface proteins are interesting targets for drug design. Results: Using methods based on proteolytic “shaving” of bacterial cells and subsequent mass spectrometry-based protein identification, we have identified surface-located proteins in Enterococcus faecalis V583. In total 69 unique proteins were identified, few of which have been identified and characterized previously. 33 of these proteins are predicted to be cytoplasmic, whereas the other 36 are predicted to have surface locations (31) or to be secreted (5). Lipid-anchored proteins were the most dominant among the identified surface proteins. The seemingly most abundant surface proteins included a membrane protein with a potentially shedded extracellular sulfatase domain that could act on the sulfate groups in mucin and a lipid-anchored fumarate reductase that could contribute to generation of reactive oxygen species. Conclusions: The present proteome analysis gives an experimental impression of the protein landscape on the cell surface of the pathogenic bacterium E. faecalis. The 36 identified secreted (5) and surface (31) proteins included several proteins involved in cell wall synthesis, pheromone-regulated processes, and transport of solutes, as well as proteins with unknown function.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0266329 A1 Mathur Et Al
    US 2012026.6329A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0266329 A1 Mathur et al. (43) Pub. Date: Oct. 18, 2012 (54) NUCLEICACIDS AND PROTEINS AND CI2N 9/10 (2006.01) METHODS FOR MAKING AND USING THEMI CI2N 9/24 (2006.01) CI2N 9/02 (2006.01) (75) Inventors: Eric J. Mathur, Carlsbad, CA CI2N 9/06 (2006.01) (US); Cathy Chang, San Marcos, CI2P 2L/02 (2006.01) CA (US) CI2O I/04 (2006.01) CI2N 9/96 (2006.01) (73) Assignee: BP Corporation North America CI2N 5/82 (2006.01) Inc., Houston, TX (US) CI2N 15/53 (2006.01) CI2N IS/54 (2006.01) CI2N 15/57 2006.O1 (22) Filed: Feb. 20, 2012 CI2N IS/60 308: Related U.S. Application Data EN f :08: (62) Division of application No. 1 1/817,403, filed on May AOIH 5/00 (2006.01) 7, 2008, now Pat. No. 8,119,385, filed as application AOIH 5/10 (2006.01) No. PCT/US2006/007642 on Mar. 3, 2006. C07K I4/00 (2006.01) CI2N IS/II (2006.01) (60) Provisional application No. 60/658,984, filed on Mar. AOIH I/06 (2006.01) 4, 2005. CI2N 15/63 (2006.01) Publication Classification (52) U.S. Cl. ................... 800/293; 435/320.1; 435/252.3: 435/325; 435/254.11: 435/254.2:435/348; (51) Int. Cl. 435/419; 435/195; 435/196; 435/198: 435/233; CI2N 15/52 (2006.01) 435/201:435/232; 435/208; 435/227; 435/193; CI2N 15/85 (2006.01) 435/200; 435/189: 435/191: 435/69.1; 435/34; CI2N 5/86 (2006.01) 435/188:536/23.2; 435/468; 800/298; 800/320; CI2N 15/867 (2006.01) 800/317.2: 800/317.4: 800/320.3: 800/306; CI2N 5/864 (2006.01) 800/312 800/320.2: 800/317.3; 800/322; CI2N 5/8 (2006.01) 800/320.1; 530/350, 536/23.1: 800/278; 800/294 CI2N I/2 (2006.01) CI2N 5/10 (2006.01) (57) ABSTRACT CI2N L/15 (2006.01) CI2N I/19 (2006.01) The invention provides polypeptides, including enzymes, CI2N 9/14 (2006.01) structural proteins and binding proteins, polynucleotides CI2N 9/16 (2006.01) encoding these polypeptides, and methods of making and CI2N 9/20 (2006.01) using these polynucleotides and polypeptides.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0044968 A1 Bolotin Et Al
    US 20110044968A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0044968 A1 Bolotin et al. (43) Pub. Date: Feb. 24, 2011 (54) COMPOSITIONS FOR TREATMENT WITH (86). PCT No.: PCT/USO9A36648 METALLOPEPTIDASES, METHODS OF MAKING AND USING THE SAME S371 (c)(1), (2), (4) Date: Nov. 5, 2010 (75) Inventors: Elijah M. Bolotin, Bothell, WA Related U.S. Application Data WA(US); (US); Gerardo Penelope Castillo, Markham, Bothell, (60) Fyal application No. 61/068.896, filed on Mar. Clifton, VA (US); Manshun Lai, s Bothell, WA (US) Publication Classification (51) Int. Cl. Correspondence Address: A638/54 (2006.01) WILSON SONSIN GOODRCH AND ROSAT f CI2N 9/96 (2006.01) PHARMAN LTD A6IP3L/00 (2006.01) 650 PAGE MILL ROAD A6IP 25/28 (2006.01) PALO ALTO, CA 94.304 (US) (52) U.S. Cl. ........................................ 424/94.3; 435/188 (57) ABSTRACT (73)73) AssigneeAssi : WPh re NC orporation,tion. SeattlSealue, The present invention is directed to biocompatible composi tions and the use of metal bridges to connect a back-bone and a metallopeptidase active agent. In certain instances, the Sub (21) Appl. No.: 12/921,670 ject compositions provide a means of achieving Sustained release of the metallopeptidase active agent after administra (22) PCT Filed: Mar. 10, 2009 tion to a subject. Patent Application Publication Feb. 24, 2011 Sheet 1 of 13 US 2011/0044968 A1 Figure 1 (1) Polymeric Backbone (branched or unbranched) 2) Chelating moieties (3) Metalions ( 4) Protective chains (5) Metallopeptidase active agent Patent Application Publication Feb. 24, 2011 Sheet 2 of 13 US 2011/0044968 A1 Figure 2 O 120% poss C D 100% O 80% w 60% s CD 20% n S PGC-NTA-Zn PGC-NTA Lysostaphin Lysostaphin Patent Application Publication Feb.
    [Show full text]
  • Protease-Armed Bacteria in the Skin
    Cell Tissue Res DOI 10.1007/s00441-012-1355-2 REVIEW Protease-armed bacteria in the skin Joanna Koziel & Jan Potempa Received: 19 January 2012 /Accepted: 25 January 2012 # The Author(s) 2012. This article is published with open access at Springerlink.com Abstract The skin constitutes a formidable barrier against degrading collagen and elastin, essential components of commensal and pathogenic bacteria, which permanently and connective tissue in the dermis. The activation of the contact transiently colonise the skin, respectively. Commensal and system and kinin generation by Streptococcus pyogenes and pathogenic species inhabiting skin both express proteases. S. aureus proteases contributes to an inflammatory reaction Whereas proteases secreted by commensals contribute to manifested by oedema, redness and pain. Kinin-enhanced homeostatic bacterial coexistence on skin, proteases from vascular leakage might help bacteria escape into the circu- pathogenic bacteria are used as virulence factors, helping lation thereby causing possible systemic dissemination of them colonise skin with breached integrity of the epithelial the infection. The inflammatory reaction can also be fueled layer. From these initial sites of colonisation, pathogens can by the activation of protease-activated receptors on kerati- disseminate into deeper layers of skin, possibly leading to nocytes. Concomitantly, bacterial proteases are involved in the spread of infection. Secreted bacterial proteases proba- degrading antimicrobial peptides, disarming the comple- bly play an important role in this process and in the deter- ment system and neutrophils and preventing the infiltration rence of innate defence mechanisms. For example, of the infected sites with immune cells by inactivation of Staphylococcus aureus proteases are essential for changing chemoattractants.
    [Show full text]